Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma (NCT01892397)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out what effects, good or bad, the Optune device has on the patient and meningioma. This study is being done because currently there are no proven effective medical treatments for a progressive meningioma that has failed surgery and/or radiation. The study uses an experimental device called Optune. Optune is "experimental" because it has not been approved by the U.S. Food and Drug Administration (FDA) for this type of tumor, although it has been approved for a different type of brain tumor.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Cedars-Sinai Medical Center — Los Angeles, California
- University of Colorado — Denver, Colorado
- University of Miami — Miami, Florida
- Memorial Sloan Kettering Cancer Center — Basking Ridge, New Jersey
- Memorial Sloan Kettering Cancer Center at Commack — Commack, New York
- Memorial Sloan Kettering West Harrison — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Columbia University — New York, New York
- University of Cincinnati — Cincinnati, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Brain Cancer
- A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma — Los Angeles, California
- Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers — Detroit, Michigan
- Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker — Lebanon, New Hampshire
- A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors — New York, New York
- Measuring the Feasibility and Effect of a Virtual Reality Cognitive Training Intervention for Brain Cancer Survivors. — Cincinnati, Ohio
Explore by condition: All Brain Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.